Search
for
Sort by
Research
390-420 / 1000+ resultsresearch Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy
Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
research Effects of androgen deprivation on chronic bacterial prostatitis in a rat model
Finasteride and levofloxacin effectively reduce chronic bacterial prostatitis severity.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research Treatment response to conventional and novel therapies in chronic prostatitis
Combining different treatments may be needed to effectively manage chronic prostatitis.
research Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice
Dutasteride works better than finasteride for preventing and treating prostate cancer.
research Commentary on BPH and Public Health—Have We Lost the Forest Through the Trees?
BPH management needs better long-term studies and prevention strategies.
research Estudo do estroma reativo prostático após a orquiectomia bilateral e posterior inibição da atividade da aromatase pela crisina e inibição da atividade da 5-alfa-redutase pela finasterida
research PD02-05 SRD5A2 EXPRESSION IS A PREDICTOR OF RESPONSE TO FINASTERIDE IN THE MTOPS TRIAL
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
research Major role for 5-alpha reductase inhibitors in the aging male
5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Influence of Clinical and Sociodemographic Factors on the Management, Costs, and Outcomes of Acute Urinary Retention in the Acute Care Setting
Early intervention for acute urinary retention can reduce costs and improve care.
research The Benefits of Dual Inhibition of 5α Reductase
Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
research RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
research Combined Sabal and Urtica extract vs finasteride in BPH (Alken stage I–II)
Sabal and Urtica extract works as well as finasteride for treating BPH, with fewer side effects.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research Discontinuation of Alpha-Blockade after Initial Treatment with Finasteride and Doxazosin for Bladder Outlet Obstruction
Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research Eficacia de la combinación de doxazosina y finasterida en la hipertrofia benigna de próstata
Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
research 1194: The Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study
Doxazosin and finasteride negatively affect sexual function in men with BPH.
research Effects of Castration on BPH
Castration significantly reduces prostate size and BPH symptoms.
research Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
research Testosterone replacement in the setting of Finasteride therapy: a therapeutic dilemma
research A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
Entadfi, a mix of finasteride and tadalafil, is used for BPH.
research 1747 PREDICTION OF BLADDER PROSTATIC OBSTRUCTION: DEVELOPMENT OF A SIMPLIFIED CLINICAL NOMOGRAM
Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.
research New Drugs: Dutasteride
Dutasteride is approved to help manage prostate enlargement.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.